FOR IMMEDIATE RELEASEChemGenex To Present At Rodman & Renshaw...

FOR IMMEDIATE RELEASE
ChemGenex To Present At Rodman & Renshaw 3rd Annual Global Healthcare Conference
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (May 11, 2006). ChemGenex
Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) will present at the Rodman & Renshaw 3rd Annual
Global Healthcare Conference in Monte Carlo on Tuesday May 16, 2006. The presentation will be at
10:10 a.m. local time in the Atlantique Salon - Western of The Le Meridien Sea Club, Monte Carlo,
Monaco.
Managing Director and Chief Executive Officer Greg Collier PhD will provide an overview of recent
highlights including;
• The successful completion of a $A15 million capital raising and an ongoing share purchase
plan (SPP) managed by ABN AMRO Morgans.
• Updates of the company’s phase 2 clinical programs, Ceflatonin® (HHT) for the treatment of
leukemias and Quinamed® (amonafide dihydrochloride) for the treatment of solid tumors.
• Status of the proposed international, multi-centre, registration directed clinical trial of
Ceflatonin in T315I mutation positive CML patients.
An audio webcast of the presentation will be available live at http://wsw.com/webcast/rrshq8/cxsp/. An
archived version of the webcast will be available at this web address for 90 days following the
presentation.
Information about the Rodman & Renshaw 3rd Annual Global Healthcare Conference can be found at
http://www.rodmanandrenshaw.com.
About ChemGenex Pharmaceuticals Limited (www.chemgenex.com)
ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the
lives of patients by developing therapeutics in the areas of oncology, diabetes, obesity, and
depression. ChemGenex harnesses the power of genomics for target discovery and validation, and in
clinical trials to develop more individualized therapeutic outcomes. ChemGenex’s lead compound,
Ceflatonin®, is currently in phase 2 clinical trials for leukemia and Quinamed® is in phase 2 clinical
trials for prostate, breast and ovarian cancers. The company has a significant portfolio of anti-cancer,
diabetes, obesity and depression programs, several of which have been partnered with international
pharmaceutical companies. ChemGenex currently trades on the Australian Stock Exchange under the
symbol "CXS" and on NASDAQ under the symbol "